Olmesartanmedoxomil/Amlodipine Stada (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil/amlodipine is indicated for management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

• Hypertension: helps achieve target blood‑pressure levels when monotherapy is insufficient.
• Hypertension with concomitant volume overload: provides additional vasodilation to improve control.
• Elderly patients with hypertension: offers a convenient once‑daily regimen that can aid adherence.
• Patients with isolated systolic hypertension: assists in lowering systolic pressure effectively.
• Hypertensive patients with metabolic syndrome: contributes to overall cardiovascular risk reduction.
• Resistant hypertension (as adjunct therapy): adds an ARB‑calcium‑channel blocker pair to overcome resistance.

• Olmesartan medoxil blocks the binding of angiotensin II to the AT1 receptor, preventing vasoconstriction and aldosterone release, while amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combined effect reduces systemic vascular resistance and lowers blood pressure.

Side‑effect profiles reflect the actions of both an ARB and a calcium‑channel blocker.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of ankles or feet.
• Dizziness or light‑headedness: especially after standing.
• Flushing: transient warmth sensation.
• Fatigue: general tiredness.
• Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of face, lips or throat.
• Severe hypotension: marked drop in blood pressure.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Acute kidney injury: sudden reduction in renal function.
• Myocardial infarction: rare but reported cardiac events.
• Hyperkalemia: elevated blood potassium levels.

When prescribing Olmesartanmedoxomil/Amlodipine, clinicians should consider several safety aspects.

• Renal impairment: adjust dose or monitor renal function regularly.
• Hepatic impairment: use with caution; monitor liver enzymes.
• Electrolyte disturbances: check potassium levels periodically.
• Pregnancy: contraindicated; avoid use in women who are pregnant or may become pregnant.
• Concomitant antihypertensives: risk of additive blood‑pressure lowering.
• Elderly patients: start at lower dose and titrate slowly.
• Store at ambient temperature: keep in original packaging.

Olmesartanmedoxomil/Amlodipine may interact with several drug classes.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: may cause hyper‑kalemia.
• Aliskiren (in diabetes): increased risk of renal impairment.
• Strong CYP3A4 inhibitors (e.g., itraconazole): raise amlodipine levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect.
• Lithium: monitor serum lithium levels.
• Rifampicin: may reduce amlodol